1st Quarter Financial Results for FYE/ Mar.2008
(Unit: Billion yen) Q1 FYE/Mar. 2007 Q1 FYE/Mar. 2008 Outside Japan sales ratio (%) ↑ 45% 48% +11.1 Growth Rate +1.9 Growth rate 17.3% i (13.1%) +2.7 Asia & Others   34.0% ¦ (24.1%) +2.8 Americas 23.2% ¦ (17.6%) Europe 24.3% i (11.0%) +3.7 Outside Japan 25.8%! (16.3%) Japan 10.5% Excluding impact of foreign exchange 3
Consolidated total: 17.3% growth ■ CV and vascular grafts
■ Home health care products
■ General hospital products (G/R: 17.8%) Q1 FYE/Mar. 2007 Q1 FYE/Mar. 2008
Q1 FYE/Mar. 2007 Q1 FYE/Mar. 2008 S.G.A Expenses rate 34.8% 32.5% ▲2.3pt Topics Terumo’s Activities in European Market
Europe is the second largest market following America ＜Market scale＞ Europe: US$ 63B *Global market in 2005: US$185B Reference : Datamonitor (2006); Espicon (2005)
Billion yen Mar. 2000  Mar. 2001  Mar. 2002  Mar. 2003  Mar. 2004  Mar. 2005  Mar. 2006  Mar. 2007 9
Sales in FYE Mar. 2000 Sales in FYE Mar. 2007 10
Billion yen ◆ Cardiovascular business has grown drastically ◆ General hospital products have shown steady sales Mar. 2003  Mar. 2004  Mar. 2005  Mar. 2006  Mar. 2007 11 @TERUMO
O : On sale   :   : : To be sold this fiscal year
Artificial vessel with built-in valve BioValsalva ♦First-in-the-world vascular grafts with built in biological valve Peripheral stent MISAGO ◆ Especially useful for thighs and armpits - To be launched in Sep. 2007 - FYE Mar. 2008: 400M yen (estimated)
Sales FYE Mar. 2007: 800M yen FYE Mar. 2008: 1,100M yen (estimated) K-pack Needles (Packaged kits for pharmaceutical companies) 14
* Excluding sales by Vascutek ① TERUMO 2
Overview ◆Strengthen of joint R&D of prefilled syringes ◆Investigation of R&D of projects integrating the liposome (TERUMO)  and Drug (KIRIN) technology ◆Investigation of joint projects regarding treatment of chronic kidney disease ◆Terumo and the Kirin Group mutually acquire stocks equivalent to 10 billion yen /TERUMO'おいしさを笑顔にKIRIN Prefilled syringes
(Unit: Million syringes) (Shipped syringe basis: From IMS data) ©2007 IMS Japan Source: IMS  JPM  April 1999 to March 2007 All rights reserved
① TERUMO Prefilled syringes
◆Higher value-added drugs - Antibody drugs, vaccines, anticancer agents, etc. ◆Higher value-added devices - Improved safety and operability - Optimization of each drug ◆Expansion and promotion of partnerships

•
Europe
–  First shipment in July, sales planned to start in Q2
• America
–  Clinical trial application planned within this fiscal year • Japan –  Selected as an early approval item

•
Europe –  Applied for CE Mark • Japan –  Clinical trial started on July 4
• Asia
–  First shipment in July, first sales commenced
Good start with double-digit growth in both sales and profits • Uncertainty including effects of foreign exchange persisting, allowing for no optimism . No revision of projected business results at this time TERUMO Corporation Corporate Communication (IR) Dept. E-mail:  CCD@terumo.co.jp This document contains forward-looking statements that reflect management’s current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.